Bayer reports better-than-expected quarterly figures

Bayer reports better-than-expected quarterly figures

The German pharmaceutical and life sciences company reported first-quarter earnings that topped consensus

Bayer revealed an EPS of €2.59, beating the €2.47 forecast. At the same time, the revenue figures came in at $12.33 billion, higher than the €12 billion initially touted.

The company’s free cash flow plummeted to -€3.23 billion, from last year’s -€793 million. The plunge was caused by the settlement payments for litigations involving its Roundup pesticide.

For the entire 2021, Bayer expects sales to clock between €42 billion and €43 billion., in line with its previous outlook.

After the news hit the wires, Bayer stock price went up almost 5%. Since the beginning of the year, its shares are up 16%.

Sources: investing.com, marketwatch.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.